Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1642 1643 1644 1645 1646 1671
This examiner grants 62% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17613881 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | Final Rejection | The Regents of the University of California |
| 17611073 | COMBINATION OF PD-1 INHIBITORS AND LAG-3 INHIBITORS FOR ENHANCED EFFICACY IN TREATING CANCER | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18061221 | METHODS OF TREATING ANKYLOSING SPONDYLITIS USING IL-17 ANTAGONISTS | Non-Final OA | Novartis AG |
| 17817925 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | Non-Final OA | Hoffmann-La Roche Inc. |
| 17611019 | METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER | Final Rejection | Board of Regents, The University of Texas System |
| 17814811 | SPLIT CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE | Final Rejection | Kite Pharma, Inc. |
| 17400689 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | Final Rejection | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 18007468 | NUCLEIC ACID ENCODED ANTIBODY MIXTURES | Non-Final OA | CureVac SE |
| 18185649 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | Non-Final OA | Immatics Biotechnologies GmbH |
| 17698617 | METHODS OF SUPPRESSING MICROGLIAL ACTIVATION | Non-Final OA | The Brigham and Women`s Hospital, Inc. |
| 18262173 | IMMUNOMODULATORY ANTIBODIES AND USES THEREOF | Non-Final OA | OncoResponse, Inc. |
| 17993567 | COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-L1 INHIBITORS | Final Rejection | HUYABIO International, LLC |
| 18253721 | ADOPTIVE CELL THERAPY FOR TREATMENT OF CANCER ASSOCIATED WITH LOSS OF HETEROZYGOSITY | Non-Final OA | A2 Biotherapeutics, Inc. |
| 18312629 | ANTI-LAG-3 ANTIBODIES | Non-Final OA | IMMUTEP S.A.S. |
| 17312317 | Screening Assays, Modulators and Modulation of Intracellular Signalling Mediated by Immunoglobulin Superfamily Cell Adhesion Molecules | Final Rejection | The University of Western Australia |
| 17998605 | SARS-COV2 NEUTRALIZING SINGLE DOMAIN ANTIBODY CONSTRUCTS | Non-Final OA | REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17915837 | EPITOPE REGION-BRIDGING BIPARATOPIC ANTIBODY AND METHOD FOR PRODUCING SAME | Non-Final OA | NATIONAL INSTITUTES OF BIOMEDICAL INOVATION, HEALTH AND NUTRITON |
| 17838118 | METHOD AND COMPOSITIONS FOR REGULATED ARMORING OF CELLS | Final Rejection | Senti Biosciences, Inc. |
| 17605061 | MEANS AND METHODS FOR TREATING BURKITT LYMPHOMA OR LEUKEMIA | Final Rejection | AMGEN RESEARCH (MUNICH) GMBH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy